- Home
- CHSCL vs HUMAW Comparison
CHSCL vs HUMAW Comparison
Compare CHSCL & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHSCL
- HUMAW
- Stock Information
- Founded
- CHSCL N/A
- HUMAW 2004
- Country
- CHSCL United States
- HUMAW United States
- Employees
- CHSCL N/A
- HUMAW N/A
- Industry
- CHSCL Farming/Seeds/Milling
- HUMAW Biotechnology: Pharmaceutical Preparations
- Sector
- CHSCL Industrials
- HUMAW Health Care
- Exchange
- CHSCL Nasdaq
- HUMAW Nasdaq
- Market Cap
- CHSCL N/A
- HUMAW N/A
- IPO Year
- CHSCL N/A
- HUMAW N/A
- Fundamental
- Price
- CHSCL $26.18
- HUMAW $1.09
- Analyst Decision
- CHSCL
- HUMAW
- Analyst Count
- CHSCL 0
- HUMAW 0
- Target Price
- CHSCL N/A
- HUMAW N/A
- AVG Volume (30 Days)
- CHSCL N/A
- HUMAW 14.2K
- Earning Date
- CHSCL N/A
- HUMAW 03-21-2025
- Dividend Yield
- CHSCL N/A
- HUMAW N/A
- EPS Growth
- CHSCL N/A
- HUMAW N/A
- EPS
- CHSCL N/A
- HUMAW N/A
- Revenue
- CHSCL N/A
- HUMAW N/A
- Revenue This Year
- CHSCL N/A
- HUMAW N/A
- Revenue Next Year
- CHSCL N/A
- HUMAW N/A
- P/E Ratio
- CHSCL N/A
- HUMAW N/A
- Revenue Growth
- CHSCL N/A
- HUMAW N/A
- 52 Week Low
- CHSCL N/A
- HUMAW $1.18
- 52 Week High
- CHSCL N/A
- HUMAW $1.34
- Technical
- Relative Strength Index (RSI)
- CHSCL 59.91
- HUMAW N/A
- Support Level
- CHSCL $25.93
- HUMAW N/A
- Resistance Level
- CHSCL $26.18
- HUMAW N/A
- Average True Range (ATR)
- CHSCL 0.17
- HUMAW 0.00
- MACD
- CHSCL 0.01
- HUMAW 0.00
- Stochastic Oscillator
- CHSCL 90.10
- HUMAW 0.00
About CHSCL CHS Inc Class B Cumulative Redeemable Preferred Stock Series 4
CHS Inc is an integrated agricultural enterprise, that provides grain, food, and energy resources to businesses and consumers. Its Energy segment produces and provides wholesale distribution of petroleum products and transportation of those products. Its Ag segment, which is the key revenue driver, purchases and processes or resells grains and oilseeds; serves as a wholesaler and retailer of crop inputs; produces and markets ethanol. Its Nitrogen Production segment consists of equity method investment in CF Nitrogen, which entitles the purchase of up to a specified quantity of granular urea and UAN annually from CF Nitrogen. Geographically, the company derives maximum revenue from North America and the rest from South America, Asia Pacific, Europe, Middle East, and Africa (EMEA).
About HUMAW Humacyte Inc. Warrant
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.